Lilly's growth is real; price, debt and retatrutide's label are the tests

The technology

Eli Lilly's business rests on incretin drugs, hormones that cut appetite and lower blood sugar. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, produced $9.94 billion and $4.93 billion in second-quarter 2026 sales, per Lilly's Q2 release. That is about 65% of the quarter's $22.97 billion in revenue. The next two products extend the same biology. Foundayo (orforglipron) is a small-molecule pill approved for obesity on April 1. Retatrutide adds a third receptor, glucagon, and produced 28.3% mean weight loss at 80 weeks in TRIUMPH-1.

Outside metabolism, Lilly has a growing oncology and neuroscience book. Jaypirca won a first-line CLL label on October 2, and the company has bought its way into sleep disorders (Centessa) and psychedelic-derived depression drugs (AtaiBeckley).

The odds

Most of the value sits in approved or late-stage assets, so classic pipeline risk is lower than for a typical biotech. Retatrutide has a complete phase 3 package and a planned U.S. filing in Q1 2027. Industry data put the odds of approval after a filing at 90.6%. The open question is the label, not approval itself: the TRIUMPH-3 cardiovascular data were inconclusive (three-point MACE HR 1.12) and dropout from side effects reached 13.5% at the top dose.

The acquired assets carry normal early-stage odds. AtaiBeckley's BPL-003 is entering phase 3, where the base rate of reaching a filing is 57.8%, and psychiatry trials tend to do worse than average.

The money

Lilly raised its 2026 revenue guide to $85 billion to $87 billion and its non-GAAP EPS guide sits at $35.50 to $36.50. Cash was $8.95 billion at June 30, against $47.86 billion of noncurrent long-term debt and $7.05 billion of current debt, per the 10-Q. Debt rose by about $11.5 billion in a single quarter as Lilly funded deals and factories, including a further $4.5 billion for Indiana sites. GlobalData figures cited by Pharmaceutical Technology put 2026 M&A spending near $32 billion by October.

The risks

Price is the first risk. Realized prices fell 13% in Q2 while volume rose 60%. Lilly is trading price for reach through cash-pay programs and discounts; PBS reported Foundayo cash prices of $149 to $349 a month. If price falls faster than volume grows, the growth story slows.

Concentration is the second. One molecule drives most of the revenue, and Novo Nordisk is fighting back with its Wegovy pill, which PBS said had more than 600,000 U.S. prescriptions within months of approval. Lilly's own indirect comparison against a higher oral semaglutide dose shows how close the oral race may be.

Deal accounting is the third. Acquired research is expensed, so each purchase can cut reported EPS, as the $3.03 per share Q2 charge did.

Our read

Lilly is a scale story now. The obesity franchise is producing growth large companies rarely see, and the pipeline behind it (oral Foundayo, then retatrutide) is late-stage and well-supported by data. The parts to watch are the ones the headline growth can hide: falling net prices, rapidly rising debt to fund a very active deal program, and a retatrutide safety profile that will shape its label. The third-quarter report on October 29 is the next hard data point on all three. After that, the retatrutide filing in early 2027 becomes the main pipeline event, and its label language on heart outcomes and tolerability will matter as much as the weight loss number itself.